Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicentre, Phase 1 Clinical Study to Evaluate the Safety and Efficacy of Zorifertinib Combined With Osimertinib in Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment

NCT07361705 is registered in ClinicalTrials.gov with Alpha Biopharma (Jiangsu) Co., Ltd. as lead sponsor.

NCT NCT07361705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07361705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicentre, Phase 1 Clinical Study to Evaluate the Safety and Efficacy of Zorifertinib Combined With Osimertinib in Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
Lead sponsor
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 31, 2026
Completion date
September 15, 2028
Enrollment
42 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

patients with advanced non-small cell lung cancer with meningeal progression after osimertinib treatment